These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 15673788)
21. Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats. Cárceles CM; Villamayor L; Escudero E; Marín P; Fernández-Varón E Vet J; 2007 Mar; 173(2):452-5. PubMed ID: 16377219 [TBL] [Abstract][Full Text] [Related]
22. In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice. Piercy T; Steward J; Lever MS; Brooks TJ J Antimicrob Chemother; 2005 Dec; 56(6):1069-73. PubMed ID: 16223941 [TBL] [Abstract][Full Text] [Related]
23. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Ahmad Z; Tyagi S; Minkowski A; Peloquin CA; Grosset JH; Nuermberger EL Am J Respir Crit Care Med; 2013 Jul; 188(1):97-102. PubMed ID: 23593945 [TBL] [Abstract][Full Text] [Related]
24. Hepatotoxicity in the treatment of tuberculosis using moxifloxacin-containing regimens. Roberts CH; Smith C; Breen R; Gadhok R; Murphy M; Aryee A; Cropley I; Bhagani S; Hopkins S; Lipman M Int J Tuberc Lung Dis; 2011 Sep; 15(9):1275-6. PubMed ID: 21943863 [No Abstract] [Full Text] [Related]
25. High doses of levofloxacin vs moxifloxacin against staphylococcal experimental foreign-body infection: the effect of higher MIC-related pharmacokinetic parameters on efficacy. Murillo O; Pachón ME; Euba G; Verdaguer R; Tubau F; Cabellos C; Cabo J; Gudiol F; Ariza J J Infect; 2009 Mar; 58(3):220-6. PubMed ID: 19217166 [TBL] [Abstract][Full Text] [Related]
28. Penetration of moxifloxacin into bone in patients undergoing total knee arthroplasty. Malincarne L; Ghebregzabher M; Moretti MV; Egidi AM; Canovari B; Tavolieri G; Francisci D; Cerulli G; Baldelli F J Antimicrob Chemother; 2006 May; 57(5):950-4. PubMed ID: 16551691 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis. Watt KM; Massaro MM; Smith B; Cohen-Wolkowiez M; Benjamin DK; Laughon MM Pediatr Infect Dis J; 2012 Feb; 31(2):197-9. PubMed ID: 22016080 [TBL] [Abstract][Full Text] [Related]
30. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328 [TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves. Pathania R; Sharma SK Res Vet Sci; 2010 Aug; 89(1):108-12. PubMed ID: 20202656 [TBL] [Abstract][Full Text] [Related]
32. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients. Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration. Zhang L; Li L; Shi W; Liu S; Liang X; Ye Z; Wang WJ; Zhang B; Li R; Chen Y; Yu C; Zhuo L; Wang X Int J Antimicrob Agents; 2013 Sep; 42(3):244-9. PubMed ID: 23876335 [TBL] [Abstract][Full Text] [Related]
34. Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Ginsburg AS; Sun R; Calamita H; Scott CP; Bishai WR; Grosset JH Antimicrob Agents Chemother; 2005 Sep; 49(9):3977-9. PubMed ID: 16127087 [TBL] [Abstract][Full Text] [Related]
35. SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease. Bermudez LE; Kolonoski P; Seitz LE; Petrofsky M; Reynolds R; Wu M; Young LS Antimicrob Agents Chemother; 2004 Sep; 48(9):3556-8. PubMed ID: 15328125 [TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics after intravenous, intramuscular and subcutaneous administration of moxifloxacin in sheep. Cárceles CM; Escudero E; Fernández-Varón E; Marín P Vet J; 2009 Jun; 180(3):343-7. PubMed ID: 18406644 [TBL] [Abstract][Full Text] [Related]
37. Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections. Ober MC; Hoppe-Tichy T; Köninger J; Schunter O; Sonntag HG; Weigand MA; Encke J; Gutt C; Swoboda S J Antimicrob Chemother; 2009 Nov; 64(5):1091-5. PubMed ID: 19734170 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis. Alffenaar JW; van Altena R; Bökkerink HJ; Luijckx GJ; van Soolingen D; Aarnoutse RE; van der Werf TS Clin Infect Dis; 2009 Oct; 49(7):1080-2. PubMed ID: 19712035 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection. Atkins HS; Spencer S; Brew SD; Laws TR; Thirlwall RE; MacMillan AP; Brooks TJ; Simpson AJ Int J Antimicrob Agents; 2009 Nov; 34(5):471-3. PubMed ID: 19682862 [TBL] [Abstract][Full Text] [Related]